(Isstories Editorial):- Mumbai, Jun 5, 2018 (Issuewire.com) – KRISHGEN BIOSYSTEMS , today announced that, it has successfully developed the first commercial testing kit for detection of Nipah Virus based on the ELISA platform. The three kits can be used to detected the Nipah virus antigen and the IgG / IgM antibodies. This helps in ensuring that patients infected over the window period of 30 days can be safely medicated the right treatment. ELISA is a well-established robust and sensitive technique. It uses the principle of antigen-antibody binding to test the sample. The company is on an overdrive to ensure the requirements are met and is supplying these kits to the medical authorities in the middle-east and Kerela.
NiV infection in humans has a range of clinical presentations, from asymptomatic infection to acute respiratory syndrome and fatal encephalitis. NiV is also capable of causing disease in pigs and other domestic animals. There is no vaccine for either humans or animals. The primary treatment for human cases is intensive supportive care.
The southern Indian state of Kerala has been put on “all-time alert” after at least 17 of the people infected with Nipah virus died in the past weeks.(*ref Al Jazeera)
The viral outbreak has resulted in the quarantine of 2,379 people in their homes in the southern state, health and government officials have said.
More than 2,000 people are under medical observation in Kerala’s Malabar region, uncertain whether they have been infected with the disease.
“Krishgen is uniquely positioned to provide life sciences products to researcher and pharmaceutical companies worldwide. We continue to deliver on our promise to bring the best technologies and products.
About KRISHGEN BIOSYSTEMS
Krishgen Biosystems, headquartered in Mumbai, India is a bio-supplier focused on offering solutions for immunoassays, cell cultures and toxicology to researchers. Krishgen offers products across the research and drug discovery segment including GENBULK, GENLISA, KRISHZYME, KRISHGEN, KRIBIOLISA, KRISHPLEX, TITANIUM.
For more information, please visit: www.krishgen.com
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding the development and commercialization of future products and our ability to bring solutions to the research and biopharmaceutical segment. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Chief Operating Officer
Unit Nos 318 319 Shah and NaharOff Dr E Moses RoadWorli